Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Tara Gangadhar on Epacadostat/ Pembrolizumab Combination

Tara C. Mitchell, MD
Published: Tuesday, Dec 01, 2015



Tara C. Mitchell, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, discuses preliminary results from a phase I/11 study of epacadostat in combination with pembrolizumab.  
 
Epacadostat, an IDO inhibitor, and pembrolizumab, a PD-1 blockade, were tested in combination in patients with various advanced cancers to evaluate the safety of the drugs together.  
 
To date, 56 patients with advanced cancers have been treated with the combination, including 20 patients with melanoma.  
 
The combination of epacadostat and pembrolizumab was shown to be exceptionally well tolerated, says MItchell, with no treatment-related deaths or grade IV toxicity. Only six patients had grade III toxicities. The early data regarding efficacy was also promising, with a response rate of 53% in patients with melanoma, says Mitchell.  


Tara C. Mitchell, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, discuses preliminary results from a phase I/11 study of epacadostat in combination with pembrolizumab.  
 
Epacadostat, an IDO inhibitor, and pembrolizumab, a PD-1 blockade, were tested in combination in patients with various advanced cancers to evaluate the safety of the drugs together.  
 
To date, 56 patients with advanced cancers have been treated with the combination, including 20 patients with melanoma.  
 
The combination of epacadostat and pembrolizumab was shown to be exceptionally well tolerated, says MItchell, with no treatment-related deaths or grade IV toxicity. Only six patients had grade III toxicities. The early data regarding efficacy was also promising, with a response rate of 53% in patients with melanoma, says Mitchell.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x